KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Net Margin (2020 - 2023)

AbCellera Biologics' Net Margin history spans 4 years, with the latest figure at 513.67% for Q4 2023.

  • For the quarter ending Q4 2023, Net Margin fell 37493.0% year-over-year to 513.67%, compared with a TTM value of 513.67% through Sep 2024, down 25740.0%, and an annual FY2024 reading of 564.83%, down 17982.0% over the prior year.
  • Net Margin for Q4 2023 was 513.67% at AbCellera Biologics, down from 433.55% in the prior quarter.
  • The five-year high for Net Margin was 59.7% in Q2 2020, with the low at 513.67% in Q4 2023.
  • Average Net Margin over 4 years is 119.2%, with a median of 21.77% recorded in 2020.
  • Year-over-year, Net Margin surged 41442bps in 2022 and then plummeted -45981bps in 2023.
  • Tracing ABCL's Net Margin over 4 years: stood at 56.28% in 2020, then decreased by -24bps to 43.03% in 2021, then crashed by -422bps to 138.75% in 2022, then plummeted by -270bps to 513.67% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Net Margin are 513.67% (Q4 2023), 433.55% (Q3 2023), and 303.58% (Q2 2023).